Trial Profile

A phase 2 trial of FG-001 in high-grade glioma (HGG)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jan 2026 According to a FluoGuide media release, the company has submitted IND application to US FDA for FG001. The IND supports the initiation of the Company' first registration trial in patients with high-grade glioma (HGG). The company expects to enroll the first patient expected in Q2 2026.
19 Dec 2025 According to a FluoGuide media release, company has announced an update to the submission date for its for its Investigational New Drug (IND) application to mid-January 2026. This updated timeline relates to the IND application supporting this registration trial for FG001.
27 Nov 2025 According to a FluoGuide media release, first patient enrollment in the U.S. Phase II registration trial expected in H1 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com